Thymosin Alpha 1

In the largest double-blind trial of thymosin alpha 1, 1,106 adults with sepsis in 22 Chinese hospitals, the peptide did not lower deaths at 28 days: 23.4 percent died on it and 24.1 percent on placebo. No secondary outcome moved either, including deaths at 90 days, organ failure scores and new infections. For sepsis mortality, that is a clear negative result, not an open question.

The safety side came out just as clearly. Adverse events and serious adverse events were as common on placebo as on the peptide, so in very sick adults it caused no harm the trial could detect. The earlier and smaller ETASS trial had pointed toward fewer deaths, and a 2025 pooling of 11 randomized trials agreed only until the weaker trials were set aside. Outside the US a synthetic version called thymalfasin (sold as Zadaxin) is approved in a number of countries. In the US it is not approved for anything.

Thymosin alpha 1 is a 28 amino acid peptide made naturally in the thymus, the gland where T cells mature. It was first isolated in 1977 from a preparation of calf thymus called thymosin fraction 5, and it was identified as the compound that restored immune function to mice whose thymus had been removed.

The material used in trials is synthetic. Its drug name is thymalfasin. It is a different molecule from thymosin beta-4, despite the shared name and the shared gland.

An Immune Signal, Not a Stimulant

The proposed picture is that thymosin alpha 1 acts on toll-like receptors, the pattern-recognition sensors immune cells use to detect infection. The reviews describe it working on dendritic cells, both myeloid and plasmacytoid, which are the cells that present threats to T cells and set the tone of the response. Switching those on starts cytokine production and pushes T cell maturation.

Lab work also links thymalfasin to more interleukin-2, more efficient antigen presentation by macrophages, and partial normalization of T cell numbers and function. That is why its research has clustered around states of immune suppression, such as severe infection, rather than around healthy immune systems.

Who Wrote the Explanation

The most detailed mechanism review in the literature, published in 2016, was written by two authors at SciClone Pharmaceuticals, the company that markets Zadaxin. That does not make the biology wrong. It does mean the mechanism story comes mostly from lab work summarized by people with a commercial stake, and when it was put to the test in TESTS, immune markers improved over four weeks at the same rate on placebo as on the peptide.

Quoting ETASS without TESTS. The 2013 trial's 26 versus 35 percent is still the number in most sales copy. The fully blinded trial built to confirm it, three times larger, found 23.4 versus 24.1 percent.

A marker moving is not a patient recovering. mHLA-DR rose faster on the peptide in ETASS. In TESTS it recovered just as well on placebo, and survival did not differ. Immune markers are why the drug was tested, not proof that it helps.

Subgroups are leads, not findings. TESTS saw a possible benefit in patients with diabetes and those 60 or older, and higher mortality in patients under 60 (hazard ratio 1.67). Neither interaction cleared the trial's own Bonferroni threshold of P = 0.006, and a post hoc look suggested the under-60 harm may not be real either. The 2025 meta-analysis rated its own diabetes and coronary heart disease signals low in credibility.

Sepsis trials say nothing about healthy people. Every trial here enrolled critically ill adults. None measured infection rates, immunity or aging in people who were well to begin with.

TESTS gives real rates, measured against placebo over 90 days. At least one adverse event occurred in 66.4 percent of treated patients and 67.6 percent on placebo; serious adverse events in 26.8 and 29.3 percent. Anaemia, fever, abdominal distension and clotting problems were the most common, at similar rates in a population this ill. No unexpected serious adverse events related to the peptide occurred. In ETASS, no serious drug-related adverse event was recorded and no patient stopped treatment over side effects, with lab safety data collected over the first week.

Reviews of the wider literature list irritation, redness or discomfort at the injection site as the most common complaint. In trials pairing thymalfasin with interferon, fever, fatigue, muscle aches, nausea, vomiting and low neutrophil counts were reported. It is listed as contraindicated in people hypersensitive to it, and in immunosuppressed patients such as transplant recipients unless the benefit outweighs the risk. All of the trial safety data comes from short courses in monitored ICU patients; none covers long-term use.

In the US it is not approved, and it sits on neither of FDA's compounding category lists. It was in Category 2, the list for substances where FDA identified significant safety risks, until about April 2026, and it left because the nominators withdrew the nomination, not because FDA resolved its concerns. Those concerns remain published. Before that, at a December 2024 meeting, FDA proposed keeping it off the list of substances pharmacies may compound from, and its advisory committee voted 17 to 4 against adding it, with members on the majority side citing a lack of convincing effectiveness data.

Thymosin alpha 1 is a real drug with a real trial record, and for sepsis that record now has an answer: in a large, fully blinded trial it was safe and it did not save lives. The effect shrank as the trials got bigger and better blinded, and in the best one it disappeared.

What is left open is narrow. Older patients and patients with diabetes are the groups TESTS and the meta-analysis point to, and a trial aimed at them could still find something. Nobody has run it yet.

What was never tested is the version sold online, a sepsis drug repackaged as everyday immune insurance. The approvals abroad are real: a 2020 review puts thymalfasin's approvals at more than 35 countries, mainly for hepatitis B and C. None of them is a US approval, and none covers general immune support in healthy adults.

Not approved in the United States. Thymalfasin is approved as Zadaxin in a number of other countries. That is not FDA approval, and nothing about its foreign status changes its US status.

Not a sepsis treatment. In 1,106 blinded, placebo-controlled patients it did not reduce deaths at 28 or 90 days, and the earlier favorable signal came from a smaller, partly blinded trial.

Not thymosin beta-4. Both come from the thymus and share part of a name, but they differ in chemical makeup and in what they do in the immune system. Evidence for one says nothing about the other.

Not tested as a wellness immune booster. The trials enrolled sick patients and measured survival and immune markers in them, not resistance to illness in healthy people.

Not clearly settled for tested sport. It is not named on the WADA Prohibited List. Whether the S0 class for non-approved substances captures it depends on its approval status abroad, and that question is unresolved.

I respect thymosin alpha 1 more than most of what gets sold next to it, and the reason is TESTS. A sponsor helped fund a 1,106-patient, fully blinded trial in the hardest population there is, and published a null result on its own product.

That result deserves to be taken at its word. For sepsis survival it did not work, and I am not going to keep quoting the 2013 number around it. It was also safe in very sick people, and that is worth saying just as plainly. The subgroup leads in older and diabetic patients are worth watching. The jump from a Chinese ICU to a wellness routine is one no trial has made, and I will not make it for them.